By D. Klingmüller, H. U. Schweikert (auth.), Professor Dr. med. Klaus Höffken (eds.)
Read Online or Download LH-RH Agonists in Oncology PDF
Best oncology books
This handbooks offers new fabric within the quickly altering box of laporoscopy and surgical oncology. Eubanks (Duke U. ), Ricardo V. Cohen and Riad N. Younes (U. of Sao Paulo), and Fredrick Brody (Cleveland sanatorium) have chosen members from a number of continents and diverse nations to supply a extensive standpoint on themes together with common ideas and physiologic adjustments, hand help units, problems and controversies, and staging and treating particular malignancies.
This completely up-to-date and multiplied moment version of Beverly Teicher's conventional vintage survey offers a step by step consultant to anticancer drug improvement from preliminary layout via FDA approval. The authors have integrated new fabric at the use of excessive throughput screening in undefined, on really good in vitro/in vivo strategies hired through the nationwide melanoma Institute (NCI) in preclinical drug reviews, and on nonclinical trying out to aid either human scientific trials, in addition to trials of biologic oncology items.
This booklet is split into 14 chapters, the 1st offering an advent to the topic and defining the goals and scope of the booklet. the quantity is meant to supply a severe evaluation of minimum entry surgical procedure within the usually circumscribed sector of surgical oncology. Its objective is to offer an goal view of the position of minimum entry surgical procedure because it pertains to verified oncological rules, prognosis and remedy.
This article offers a transparent, reproducible, step by step advisor for every colorectal surgical procedure operation. The structure follows that of either a “how to” handbook in addition to an algorithm-based advisor to permit the reader to appreciate the idea technique in the back of the proposed remedy process. each one bankruptcy contains either operative technical information in addition to perioperative “tips and methods” that the authors make the most of within the administration of those complicated surgical sufferers.
- Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies
- Targeted Therapy in Translational Cancer Research
- Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents
- Prostate Cancer New Horizons in Research and Treatment
- Chemotherapy-Induced Neuropathic Pain
Additional info for LH-RH Agonists in Oncology
Under our experimental conditions, the inhibitory effects of buserelin were achieved at rather high concentrations. Medium was routinely changed after 3 and 5 days and this may have caused proteolytic breakdown of the LH-RH agonist. In medium containing fetal calf serum Miller et al.  were able to obtain complete growth inhibition, and even a net decrease in MCF-7 cell number at buserelin concentrations as low as 1 nM after 4 days of culture, during which medium was changed daily. Addition of a higher dose, i.
BioI Reprod 22: 383-391 Conn PM, Hsueh AJW, Crowley WF (1984) Gonadotropin-releasing hormone: molecular and cell biology, physiology and clinical applications. Fed Proc 43: 2351-2361 Donaubauer HR, Kramer M, Krieg H, Mayer D, Rechenberg W v, Sandow J, Schiitz E (1987) Investigations of the carcinogenicity of the LH-RH analogue buserelin (HOE 766) in rats using the subcutaneous route of administration. Fundam Appl Toxicol 9: 738-752 Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro.
Subsequently, using the same protocol, 13 patients were treated with a combination of buserelin and cyproterone acetate, a potent antiandrogen. There was only one difference in admission criteria: all patients in study II were required to have an elevated serum acid phosphatase. Patient characteristics at entry are shown in Table 1. More that 18% had bone metastases. There was a surprisingly high incidence of lymph node metastases. More than one-half of the patients had tumor-related symptoms. tg per 24 h.
LH-RH Agonists in Oncology by D. Klingmüller, H. U. Schweikert (auth.), Professor Dr. med. Klaus Höffken (eds.)